All data are based on the daily closing price as of October 22, 2025
s
Samsung Biologics
207940.KO
698.51 USD
-0.88
-0.13%
Overview
Last close
698.51 usd
Market cap
49.72B usd
52 week high
761.21 usd
52 week low
522.84 usd
Target price
698.51 usd
Valuation
P/E
N/A
Forward P/E
37.1747
Price/Sales
16.564
Price/Book Value
6.2201
Enterprise Value
50.25B usd
EV/Revenue
14.2981
EV/EBITDA
31.742
Key financials
Revenue TTM
3.51B usd
Gross Profit TTM
1.85B usd
EBITDA TTM
1.59B usd
Earnings per Share
N/A usd
Dividend
N/A usd
Total assets
13.13B usd
Net debt
465.98M usd
About
Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. The company operates through Contract Development and Manufacturing Organization (CDMO), and Biopharmaceutical Development and Commercialization segments. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and regulatory support services; and quality, biosafety and analytical testing services, as well as manufactures drug substance. In addition, it engages in the development and commercialization of biosimilar drugs; development and manufacture of antibody-drug conjugates and mRNA products. The company was founded in 2011 and is headquartered in Incheon, South Korea.